Merck and Sanofi sound the alarm for ILT inhibition
Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.
FDA red and green lights: January 2025
AstraZeneca bags three of the month’s four oncology approvals.
A Leap into the subgroups
On a wing and a prayer Leap heads for phase 3.
ASCO-GI – a second colorectal win for Bristol's combo
Opdivo and Yervoy succeed again, but the US path remains unclear.
ASCO-GI – Exelixis’s son of Cabometyx disappoints
The company might need something better to replace its ageing blockbuster.
